Relapse · guttate psoriasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse · people with chronic plaque psoriasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse · guttate psoriasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse · guttate psoriasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intraperitoneal pain (NRS; higher = more pain) · women undergoing PPTL under local anaesthesia
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Intraperitoneal pain (NRS; higher = more pain) · women undergoing PPTL under local anaesthesia
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Adverse effects: at least one serious adverse event · people in the prodromal stage of psychosis
1 finding from 1 review
Adverse effects: at least one serious adverse event · people in the prodromal stage of psychosis
1 finding from 1 review
Adverse effects: at least one serious adverse event · people in the prodromal stage of psychosis
1 finding from 1 review
Resolution of daytime urinary incontinence · children aged 5 to 14 years with overactive bladder and at least one episode of daytime urinary incontinence per week
It is very uncertain whether timer watch plus standard urotherapy changes resolution of daytime urinary incontinence after 3 months of treatment compared with standard urotherapy alone (very low certainty).
1 finding from 1 review
Frequency of incontinence episodes · children aged 5 to 14 years with overactive bladder and at least one episode of daytime urinary incontinence per week
It is very uncertain whether timer watch plus standard urotherapy changes frequency of incontinence episodes at 3 months compared with standard urotherapy alone (very low certainty).
1 finding from 1 review
Objective measurement of volume of incontinent episodes · children aged 5 to 14 years with overactive bladder and at least one episode of daytime urinary incontinence per week
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Resource implications (e.g. cost of incontinence management methods) · children aged 5 to 14 years with overactive bladder and at least one episode of daytime urinary incontinence per week
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life measurements · children aged 5 to 14 years with overactive bladder and at least one episode of daytime urinary incontinence per week
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects · children aged 5 to 14 years with overactive bladder and at least one episode of daytime urinary incontinence per week
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: at least one serious adverse event · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…
Palliative care showed no clear difference in serious adverse events Assessed by: number of participants… compared with usual care (low certainty).
1 finding from 1 review
Intervention not reported
Sulfasalazine + prednisolone (1 RCT; 57 participants) · surgically induced remission in Crohn's disease
It is very uncertain whether the intervention changes sulfasalazine + prednisolone (1 RCT; 57 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Acetazolamide versus medroxyprogesterone: risk of AMS · participants at risk of high altitude illness
The intervention showed no clear difference in acetazolamide versus medroxyprogesterone: risk of AMS (low certainty).
1 finding from 1 review
Intervention not reported
Acetazolamide + medroxyprogesterone versus medroxyprogesterone: risk of AMS · participants at risk of high altitude illness
The intervention showed no clear difference in acetazolamide + medroxyprogesterone versus medroxyprogesterone: risk… (low certainty).
1 finding from 1 review
Intervention not reported
Acetazolamide + medroxyprogesterone versus acetazolamide: risk of AMS · participants at risk of high altitude illness
The intervention showed no clear difference in acetazolamide + medroxyprogesterone versus acetazolamide: risk of AMS (low certainty).
1 finding from 1 review